Remternetug
Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.
Overview
Listed so the pipeline layer of the Alzheimer’s page has a concrete next antibody. Risks should not be copied from lecanemab or donanemab by assumption.
Investigational amyloid-directed antibody. Connects to Amyloid-beta.
1.Remternetug binds Amyloid-beta.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Remternetug" OR ABSTRACT:"Remternetug" OR TITLE:"LY3372993" OR ABSTRACT:"LY3372993") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Remternetug, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialEXPEDITION 3
Shares Eli Lilly, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Eli Lilly, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentDonanemab
Shares Amyloid-beta, Eli Lilly, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- PathwayAmyloid and tau cascade (simplified)
Shares Amyloid-beta, Alzheimer’s disease and the tag dementia-atlas.
- TrialENGAGE
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentAducanumab
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- IdeaBlood test before PET or lumbar puncture
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentLecanemab
Shares Amyloid-beta, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.